Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

RPT-INSIGHT-Corporate sleuths on edge after China detains foreign consultants

Wed, 31st Jul 2013 20:37

* Foreign couple's firm did work for GlaxoSmithKline, otherdrugmakers

* Unclear why they have been detained

* Other corporate investigators informally questioned -sources

* Foreign investigators nervous, cutting back on email use

* China investigating people for crimes over use ofinformation

By Alexandra Harney

SHANGHAI, July 31 (Reuters) - The detention by Chineseauthorities of a British corporate investigator and his Americanwife in the wake of a corruption probe into pharmaceutical giantGlaxoSmithKline has had a chilling effect on other riskconsultants working in China.

It's unclear why Peter Humphrey and Yu Yingzeng, whose firmChinaWhys has done work for GSK and other drugmakers, weredetained. But corporate investigators said they were concernedabout the repercussions for the industry.

Multinationals, banks and investors rely on corporateinvestigators for information about potential partners andinvestments in China, where a lack of transparency is a hurdleto doing business. Restrictions in the flow of such backgroundinformation could potentially leave foreign investors exposed togreater risk in the world's second-largest economy.

ChinaWhys offers "discreet risk mitigation solutions,internal process audits, due diligence and commercialinvestigation services", according to the firm's website.

"(Humphrey's) detention is really disturbing. It gives me anuneasy feeling that people who, on the face of it, are trying tohelp companies and individuals navigate their way around thesystem are being targeted," said Gary Miller, litigation partnerand head of the fraud group at London law firm Mishcon de Reya.

Mike Vermillion, senior director of third party riskmanagement solutions at Oregon-based consultancy Navex Global,called the detentions chilling.

"I am certainly not getting on a plane to China next week,"Vermillion said.

Two sources with direct knowledge of the matter have saidHumphrey and Yu were detained by Chinese authorities in Shanghaion July 10. They did not specify who was holding the couple.

A Shanghai police spokesman said police there had neitherdetained nor had any contact with Humphrey. He said Humphrey'scase was being handled by Beijing. Police in the capitaldeclined to comment.

British diplomats have said they were giving consularassistance to a Briton detained in Shanghai but have declined toprovide further details. U.S. diplomats have said the same thingabout a detained American. Reuters has not been able todetermine if the couple have a lawyer.

OTHER INVESTIGATORS QUESTIONED

Their detention has not been an isolated case.

Two industry executives said investigators from othercompanies were being "invited for tea" by Shanghai authorities,a euphemism for informal questioning in China.

Some investigators, worried they are under surveillance,have scaled back their use of email. Some declined to speak toreporters over the phone, afraid that authorities were listeningin to their conversations.

Several investigators said that they had become morecautious about which projects to accept, avoiding any thegovernment might see as sensitive.

Investigators said they had also heard of people requestingreassignment to Hong Kong, which has a separate legal system tomainland China. These movements could not be confirmed.

A series of incidents in recent years has highlightedChina's growing willingness to investigate, detain and prosecutepeople for crimes involving the use of information forcommercial purposes.

Corporate investigators first came under China's microscopelast year after a spate of accounting scandals at U.S.-listedChinese firms that led to forced delistings, shareholderlawsuits and investigations by overseas regulators.

Many of the scandals followed reports by short-sellers whoaccused the firms of financial irregularities.

Some corporate investigators in China had worked withshort-sellers and hedge funds doing research on those companies,said Paul Gillis, professor at Peking University's GuanghuaSchool of Management. It is unclear if the recent detentions arerelated to that work. Short-sellers borrow shares, sell them inthe expectation that their price will fall and then buy themback at a lower price.

"I know there's been a great deal of unhappiness with theactivities of short sellers ... That's been one of the thingsthat China has been quite irritated about," said Gillis.

Jon Carnes, a U.S.-based short-seller who attacked severalChinese companies between 2010 and 2011 using the pseudonymAlfred Little, has said one of his Chinese researchers had beenjailed in China.

INDUSTRY HAS GROWN RAPIDLY

The corporate investigations business has expanded rapidlyin China in recent years in response to concern about complianceissues, in the wake of increased enforcement of the U.S. ForeignCorrupt Practices Act (FCPA) and a surge in international dealsinvolving Chinese firms.

The big four international accounting firms -- KPMG, PriceWaterhouseCoopers, Deloitte and Ernst & Young, along with companies such asControl Risks, FTI Consulting and Kroll are among the largestoperating in China.

Investigators say the industry has also grown to includehundreds of small companies and individual operators as well,including ChinaWhys, a consultancy founded by Humphrey in 2003.Humphrey is a former journalist who worked for Reuters for 16years until 1998.

British drugmaker GSK has declined to comment on the workChinaWhys did for the firm except to say that Humphrey is not,nor has he ever been, an employee.

GSK is in crisis in China after police this month accused itof funnelling up to 3 billion yuan ($489 million) to travelagencies to facilitate bribes to doctors and officials. Thecompany, Britain's biggest pharmaceutical maker, has said someof its Chinese executives appeared to have broken the law.

With the investigation industry's expansion in China,particularly among smaller firms, came an illegal trade inprivate information, including bank, telephone, and even hukouor household registration records, investigators said. Someinvestigators claimed they could place moles inside companies.

"Parts of the investigations industry in China were flyingvery close to the sun from a legal standpoint for a very longtime," said Velisarios Kattoulas, chief executive of PoseidonGroup, a risk management consultancy active in China.

Starting as early as late last year, police beganquestioning hundreds of people involved in the trade ofprotected information, according to several investigators.

At least one small investigations company in China closeddown as a result, investigators said. It was not clear if thisfirm was run by expatriates or locals.

LEGAL GREY AREA

Investigators concede some parts of their work stray into alegal grey area in China. Private investigations are prohibitedunder a 1993 Ministry of Public Security notice, though this,like other laws and regulations in China, has only beenselectively enforced.

One Chinese lawyer who works with investigation companiessaid that because they cannot get business licences as privateinvestigators, such firms often register as "business advisors".This can leave them in a legally precarious situation.

"The negative part of this is that the government can getyou whenever they want," this lawyer said.

It is not only corporate investigators who have fallen foulof Chinese law on the commercial use of information.

In December 2012, a Chinese court sentenced four formerexecutives from a Shanghai unit of Dun & Bradstreet, aglobal business information firm, to prison for illegally buyinginformation about Chinese consumers. Dun & Bradstreet said inMay last year it was shutting the unit.

The scrutiny on corporate investigators comes as Chinaprepares to reopen its equity markets to initial publicofferings after unofficially halting IPOs last October as partof a crackdown on fraud.

It is unclear if any investigators were caught up in thatcrackdown.

At the same time, the government has been tightening accessto corporate records. Last summer, it began restricting theavailability of corporate filings to China's main businessregistry, the Administration of Industry and Commerce. Theserestrictions are still in force, investigators say.

More News
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more
4 Jan 2024 14:01

UK dividends calendar - next 7 days

Friday 5 January 
British Land Co PLCdividend payment date
Hill & Smith PLCdividend payment date
JD Sports Fashion PLCdividend payment date
JPMorgan Global Growth & Income PLCdividend payment date
Liontrust Asset Management PLCdividend payment date
Lok'n Store Group PLCdividend payment date
Real Estate Credit Investments Ltddividend payment date
RS Group PLCdividend payment date
Tate & Lyle PLCdividend payment date
Monday 8 January 
abrdn Equity Income Trust PLCdividend payment date
Intermediate Capital Group PLCdividend payment date
Tuesday 9 January 
no events scheduled 
Wednesday 10 January 
Assura PLCdividend payment date
Bellway PLCdividend payment date
Fidelity Special Values PLCdividend payment date
LXi REIT PLCdividend payment date
Severn Trent PLCdividend payment date
Volex PLCdividend payment date
Vp PLCdividend payment date
Thursday 11 January 
AJ Bell PLCex-dividend payment date
Ashtead Group PLCex-dividend payment date
BlackRock Latin American Investment Trust PLCex-dividend payment date
CMC Markets PLCdividend payment date
dotdigital Group PLCex-dividend payment date
Ecora Resources PLCex-dividend payment date
European Assets Trust PLCex-dividend payment date
Foresight Group Holdings Ltdex-dividend payment date
GSK PLCdividend payment date
ICG-Longbow Senior Secured UK Property Debt Investments Ltdex-dividend payment date
JPMorgan Asia Growth & Income PLCex-dividend payment date
Keystone Positive Change Investment Trust PLCex-dividend payment date
LondonMetric Property PLCdividend payment date
Murray International Trust PLCex-dividend payment date
National Grid PLCdividend payment date
Primary Health Properties PLCex-dividend payment date
Sage Group PLCex-dividend payment date
Smiths News PLCex-dividend payment date
SSE PLCex-dividend payment date
Supermarket Income REIT PLCex-dividend payment date
TR Property Investment Trust PLCdividend payment date
Walker Crips Group PLCex-dividend payment date
WH Smith PLCex-dividend payment date
Worldwide Healthcare Trust PLCdividend payment date
XPS Pensions Group PLCex-dividend payment date
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.